BBNX
Beta Bionics, Inc. Common Stock
NASDAQ: BBNX · HEALTHCARE · MEDICAL DEVICES
$9.90
-1.79% today
Updated 2026-04-29
Market cap
$441.16M
P/E ratio
—
P/S ratio
4.00x
EPS (TTM)
$-1.37
Dividend yield
—
52W range
$9 – $33
Volume
1.2M
Beta Bionics, Inc. Common Stock (BBNX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $179000.00 | $11.99M | $65.12M | $100.25M |
| Revenue growth (YoY) | — | +6601.1% | +442.9% | +53.9% |
| Cost of revenue | — | $5.69M | $29.24M | $44.71M |
| Gross profit | $179000.00 | $6.31M | $35.89M | $55.54M |
| Gross margin | 100.0% | 52.6% | 55.1% | 55.4% |
| R&D | $31.43M | $17.94M | $26.18M | $34.79M |
| SG&A | $24.67M | $12.22M | $17.87M | $31.02M |
| Operating income | $-65.84M | $-35.85M | $-45.25M | $-71.68M |
| Operating margin | -36784.4% | -298.9% | -69.5% | -71.5% |
| EBITDA | $-63.40M | $-34.62M | $-44.10M | $-73.20M |
| EBITDA margin | -35418.4% | -288.7% | -67.7% | -73.0% |
| EBIT | $-64.74M | $-35.85M | $-45.25M | — |
| Interest expense | $14000.00 | $68000.00 | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-64.75M | $-44.10M | $-54.76M | $-73.20M |
| Net income growth (YoY) | — | +31.9% | -24.2% | -33.7% |
| Profit margin | -36173.7% | -367.6% | -84.1% | -73.0% |